ar-c239 has been researched along with apraclonidine in 1 studies
| Studies (ar-c239) | Trials (ar-c239) | Recent Studies (post-2010) (ar-c239) | Studies (apraclonidine) | Trials (apraclonidine) | Recent Studies (post-2010) (apraclonidine) |
|---|---|---|---|---|---|
| 45 | 0 | 5 | 427 | 98 | 56 |
| Protein | Taxonomy | ar-c239 (IC50) | apraclonidine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.004 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.004 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alburges, ME; Bylund, DB; Pundt, LL; Wamsley, JK | 1 |
1 other study(ies) available for ar-c239 and apraclonidine
| Article | Year |
|---|---|
Alpha 2-agonist binding sites in brain: [125I]para-iodoclonidine versus [3H]para-aminoclonidine.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Autoradiography; Binding, Competitive; Brain; Clonidine; Iodine Radioisotopes; Isoquinolines; Male; Oxymetazoline; Piperazines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Tritium | 1993 |